The German Federal Joint Committee (G-BA) - the country's self-governing medical system - has confirmed its belief that anticancer agent Halaven may offer additional benefits versus comparative treatments.
The drug - which is also known as eribulin mesylate - is the first single-agent chemotherapy treatment for people with pretreated metastatic breast cancer that has demonstrated a significant overall survival benefit.
Eisai is currently conducting further clinical research into Halaven in order to establish its effectiveness in fighting other forms of cancer.
It was noted the G-BA's assessment differs from a report published by the German Institute for Quality and Efficiency in Health Care in February.
However, G-BA were able to demonstrate that Halaven does indeed offer an improved survival rate and Eisai claims it is good news for innovative medicines in the area of oncology.
Eisai underlined its commitment to addressing the needs of cancer patients and increasing the benefits made available to them.